ArticleJournal of controlled release : official journal of the Controlled Release Society2020
Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Validation of an automated AI-based micro-CT organ segmentation workflow against expert annotations and its impact on fluorescence quantification.European radiology experimental · 2026Article
- Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning.Nature biotechnology · 2025Article
- Development of GSH-Stimuli-Responsive Micelles Using a Targeted Paclitaxel Prodrug for Enhanced Anticancer Effect.Pharmaceutics · 2025Article
- Nanoodor Particles Deliver Drugs to Central Nervous System via Olfactory Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Click Chemistry for Biofunctional Polymers: From Observing to Steering Cell Behavior.Chemical reviews · 2024Review
- Emergence and impact of theranostic-nanoformulation of triple therapeutics for combination cancer therapy.Smart medicine · 2024Review
- Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications.Materials today. Bio · 2024Review
- Repurposing Tamoxifen for Tumor Microenvironment Priming and Enhanced Tumor-Targeted Drug Delivery.Advanced therapeutics · 2023Article
- Profiling target engagement and cellular uptake of cRGD-decorated clinical-stage core-crosslinked polymeric micelles.Drug delivery and translational research · 2023Article
- Nanoparticle Diagnostics and Theranostics in the Clinic.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications.Journal of nanobiotechnology · 2022Review
- Bioinspired Threonine-Based Polymers with Potent Ice Recrystallization Inhibition Activity.ACS applied polymer materials · 2022Article
- Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer.3 Biotech · 2022Review
- Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution.Theranostics · 2022Article
- Imaging-guided nanomedicine development.Current opinion in chemical biology · 2021Review
- The past, present, and future of breast cancer models for nanomedicine development.Advanced drug delivery reviews · 2021Review
- New Aspects of Kidney Fibrosis-From Mechanisms of Injury to Modulation of Disease.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
Abstract
Core-crosslinked polymeric micelles (CCPM) based on PEG-b-pHPMA-lactate are clinically evaluated for the treatment of cancer. We macroscopically and microscopically investigated the biodistribution and target site accumulation of CCPM. To this end, fluorophore-labeled CCPM were intravenously injected in mice bearing 4T1 triple-negative breast cancer (TNBC) tumors, and their localization at the whole-body, tissue and cellular level was analyzed using multimodal and multiscale optical imaging. At the organism level, we performed non-invasive 3D micro-computed tomography-fluorescence tomography (μCT-FLT) and 2D fluorescence reflectance imaging (FRI). At the tissue and cellular level, we performed extensive immunohistochemistry, focusing primarily on cancer, endothelial and phagocytic immune cells. The CCPM achieved highly efficient tumor targeting in the 4T1 TNBC mouse model (18.6 %ID/g), with values twice as high as those in liver and spleen (9.1 and 8.9 %ID/g, respectively). Microscopic analysis of tissue slices revealed that at 48 h post injection, 67% of intratumoral CCPM were localized extracellularly. Phenotypic analyses on the remaining 33% of intracellularly accumulated CCPM showed that predominantly F4/80
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.